Bull case
Eupraxia Pharmaceuticals is supported by a differentiated local-delivery platform, Diffusphere, that underpins EP-104GI’s ability to sustain remission and histologic benefit through 52 weeks after a single administration, with Cohort 9 showing 66% remission at Week 52 and a mean SDI reduction of 3.0 points. The investment case is strengthened by the addressable EoE market’s ~10.5% growth, the limited set of approved competitors, and management’s view that annual dosing could move the product ahead of chronic swallowed steroids and potentially biologics, while the Phase 2b knee OA program adds validation across indications. Financially, the company’s model highlights substantial upside potential, with cash above $100MM, a projected FY34 revenue of $1.3B, and a conservative valuation framework that improves if upcoming randomized efficacy readouts confirm durable, commercially meaningful activity.